Distinguished in Scleroderma

Patrick Jego

Rennes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Scleroderma
Rennes, FR 
OverviewLocationsClinical Research

Overview

Patrick Jego practices in Rennes, France. Mr. Jego is rated as a Distinguished expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Takayasu Arteritis, and Eosinophilic Fasciitis.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 40 articles and participated in 2 clinical trials in the study of Scleroderma.

Gender
Male

Locations

Rennes, 35000, France
Other Locations
Toulouse, France
Marseille, France
Tours, France
France
Saint-etienne-de-valoux, France
Redon, France
Nantes, 44093, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Enrollment Status: Recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages
Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages
Enrollment Status: Active_not_recruiting
Publish Date: April 12, 2023
Intervention Type: Other
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Enrollment Status: Completed
Publish Date: June 24, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital
In-hospital Falls and Hemorrhagic Complications : a Descriptive Analysis in Rennes University Hospital
Enrollment Status: Completed
Publish Date: December 19, 2018
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Enrollment Status: Terminated
Publish Date: July 20, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

114 Total Publications

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study.
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study.
Journal: Rheumatology (Oxford, England)
Published: October 28, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jego's expertise for a condition
ConditionClose
    View All 48 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile